Perspectives and opportunities for precompetitive public-private partnerships in the biomedical sector

Biotechnology Law Report

Volumn 32, Issue 3, 2013, Pages 131-139

  Stevens, H ^a,b   Van Overwalle, G ^b,c   Van Looy, B ^c,d,e,f   Huys, I ^a,b  

^a Research Centre for Pharmaceutical Care and Pharmacoeconomics O and N II   (Belgium)

^b University of Leuven ^*  (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d TILBURG UNIVERSITY   (Netherlands)

^e Centre for Research and Development Monitoring (ECOOM)   (Belgium)

^f UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879167020     PISSN: 0730031X     EISSN: None     Source Type: Journal    
DOI: 10.1089/blr.2013.9929     Document Type: Article

References (49)

1. Scudellari M. Clinical drive prompts pharma and academia to partner up. Nat Med 2011;17:3.
2. Wagner JA. Open-minded to open innovation and precompetitive collaboration. Clin Pharmacol Ther 2010;87:511-515.
3. Widdus R. Public-private partnerships: an overview. Trans R Soc Trop Med Hyg 2005;99(Suppl 1):S1-S8.
4. Lenford H. Drug buddies. Nature 2011;474:433-443 [cited June 23, 2011].
5. Munos BH, Chin WW. A call for sharing: adapting pharmaceutical research to new realities. Sci Transl Med 2009;1(9): 9cm8.
6. Munos BH Can open-source drug R&D repower pharmaceutical innovation? Clin Pharmacol Ther 2010;87:534-536.
7. Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med 2009;15:502-507.
8. Kling J. Biotechs follow big pharma lead back into academia. Nature Biotechnol 2011;29:555-556.
9. Mullard A. Partnering between pharma peers on the rise. Nature Rev 2011;10:561-562.
10. Gold ER, Bubela T, Carbone J, Gagnon MA, Srulovicz T, Joly Y. At the intersection of health and intellectual property: issues, tools and directions for Health Canada. 30-3-2010. The Innovation Partnership (TIP).
11. Williams RS, Desmond-Hellman S. Making translation work. Science 2011;332:1359.
12. Woodcock J Precompetitive research: a new prescription for drug development? Clin Pharmacol Ther 2010;87:521-523.
13. Mullard A Could pharma open its drugs freezers? Nature Reviews 2011;10:399-400.
14. Gallagher WM, Tweats D, Koenig J Omic profiling for drug safety assessment: current trends and public-private partnerships. Drug Discov Today 2009;14:337-342.
15. Croft SL. Public-private partnership: from there to here.
16. Trans R Soc Trop Med Hyg 2005;99(Suppl 1):S9-S14.
17. Demotes-Mainard J, Canet E, Segard L. Public-private partnership models in France and in Europe. Therapie 2006;61:325-323.
18. European PPP Expertise Centre (EPEC). Market Update. Review of the European PPP Market in 2010. 2011.
19. Reich MR. Public-private partnerships for public health. Nat Med 2000;6:617-620.
20. Ridley RG. Putting the partnership into public-private partnerships. Bull World Health Org 2001;79:694.
21. Wagner JA, Prince M, Wright EC. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration. Clin Pharmacol Ther 2010;87:539-542.
22. Widdus R. Public-private partnerships for health: their main targets, their diversity, and their future directions. Bull World Health Organ 2001;79:713-720.
23. Goldman M. Reflections on the Innovative Medicines Initiative. Nat Rev 2011;10:321-322.
24. Cain C. Making the case for precompetitive clinical development. Science-Business eXchange 2011;4(20). Expanding precompetitive space. Nat Rev Drug Discovery 2011;10:883.
25. Cressey D. Traditional drug-discovery model ripe for reform. Nature 2011;471:17-18.
26. Napa J Open source drug discovery: a feasible business model? Pharma Focus Asia 2011.
27. Vargas G, Boutouyrie B, Ostrowitzki S, Santarelli L. Arguments against precompetitive collaboration. Clin Pharmacol Ther 2010;87:527-529.
28. Moran N. New models emerge for commercializing university assets. Nat Biotechnol 2011;29:774-775.
29. Borshell N Is deal-making becoming more difficult? Nat Rev 2011;10:404.
30. Opar A. Bridging the drug-diagnostic divide. Nat Rev 2011;10:323-324.
31. Richter J Public-private partnerships for health: a trend with no alternatives? Development 2004;47(2):43-48.
32. Widdus R. Public-private partnerships for health require thoughtful evaluation. Bull World Health Org 2003;81:235.
33. Yescombe ER. Public-private partnerships: principles of policy and finance. Butterworth-Heinemann (Elsevier), 2011.
34. Geddes M. Making public private partnerships work: building relationships and understanding cultures. Gower Publishing Limited, 2005.
35. Treaty on European Union (EU), 7 February 1992. O.J. (C191) 1, 31 I.L.M. 253. 7-2-1992.
36. Nwaka S. Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. Trans R Soc Trop Med Hyg 2011;99S:S20-S29.
37. Martin JF, Marshall J. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund. Vaccine 2003;21:587-592. www.mmv.org/research-development/r-d-process http://lrd.kuleuven.be/en/tc/cd3-1/ cd3-discovery-of-innovativemedicines, 2011.
38. Gulbranson CA, Audretsch DB. Proof of concept centers: accelerating the commercialization of university innovation. J Technol Transfer 2008;33:249-258.
39. Rai AK, Reichman JH, Uhlir PF, Crossman C. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. In: Van Overwalle G, editor.
40. Gene Patents and Collaborative Licensing Models. Patent Pools, Clearinghouses, Open Source Models and Liability Regimes. New York: Cambridge University Press, 2009, pp 247-288.
41. Ciccone DK. Arguing for a centralized coordination solution to the public-private partnership explosion in global health. Global Health Promotion 2010;17(48).
42. Van Looy B, Landoni P, Callaert J, van Pottelsberghe B, Sapsalis E, Debackere K. Entrepreneurial effectiveness of European universities: an empirical assessment of antecedents and trade-offs. Research Policy 2011;40:553-564.
43. Gilbert N. Universities shun Europe's drug initiative. Nature 2010;466:306-307.
44. Merz JF. Intellectual Property and Product Development Public/Private Partnerships. Final Report, May 16, 2005 to the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health. 2005.
45. Bereuter TL, Jerolitsch D, Heimerl P. IPR Codes and Guidelines in Europe Facilitating Collaboration of Publicly Funded Research Organizations (PROs) with Businesses (Part 1). les Nouvelles 2011; September: 226-236.
46. Schmidt C. Debate re-ignites on contribution of public research to drug development. Nat Biotechnol 2011;29:469-470.
47. Kotz J. Small (molecule) thinking in academia. Science-Business eXchange 2011;4(22):1-4.
48. Strohmeier R, Draghia-Akli R, Rys A, et al. IMI moves forward. Nat Biotechnol 2011;29:689-790.
49. Saez C. Partnership to share research, keep IP rights, on neglected diseases. http://www.ip-watch.org/2011/06/01/partnershipto-share-research-keep- ip-rights-on-neglected-diseases/